On Dec 8, 2018 AC Immune SA (NASDAQ:ACIU) Shorts Rose By 0.88%

Change of 0.88% for AC Immune SA (NASDAQ:ACIU)’s shorted shares was registered. In December was published ACIU’s total 1.41 million shorted shares by FINRA. The 1.39M previous shares are up with 0.88%. Previous ACIU’s position will need 9 days to restore. It has 153,000 average volume. AC Immune SA’s shorted shares float is 4.26%.

ACIU reached $11.15 during the last trading session after $0.49 change.Currently AC Immune SA is downtrending after 19.43% change in last December 8, 2017. ACIU has 76,957 shares volume. The stock underperformed the S&P500 by 35.05%.

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding.The company has $751.09 million market cap. The Company’s SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as AlzheimerÂ’s , ParkinsonÂ’s, down syndrome, and glaucoma diseases.Currently it has negative earnings. The companyÂ’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies.

For more AC Immune SA (NASDAQ:ACIU) news brought out recently go to: Benzinga.com, Seekingalpha.com, Globenewswire.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Alzheimer’s Drug Pipeline: High Failure Rates In Research On An Increasingly Common Disease – Benzinga” brought out on February 08, 2018, “AC Immune IPO Has Potential But Proceed With Caution – Seeking Alpha” on September 14, 2016, “AC Immune Announces Closing of First Subscription Rights Offering and Primary Offering as well as Full Exercise of Option to Purchase Additional Shares – GlobeNewswire” with a publish date: July 23, 2018, “AC Immune (ACIU) Shares March Higher, Can It Continue? – Nasdaq” and the last “AC Immune: A Compelling Speculative Investment – Seeking Alpha” with publication date: July 11, 2017.

AC Immune SA (NASDAQ:ACIU) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.